Charles River Laboratories International, Inc. (CRL)
Market Cap | 6.94B |
Revenue (ttm) | 4.02B |
Net Income (ttm) | -31.56M |
Shares Out | 49.12M |
EPS (ttm) | -0.62 |
PE Ratio | n/a |
Forward PE | 14.45 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,330,409 |
Open | 139.44 |
Previous Close | 136.97 |
Day's Range | 139.43 - 143.47 |
52-Week Range | 91.86 - 254.15 |
Beta | 1.50 |
Analysts | Hold |
Price Target | 184.00 (+30.16%) |
Earnings Date | May 7, 2025 |
About CRL
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use o... [Read more]
Financial Performance
In 2024, CRL's revenue was $4.05 billion, a decrease of -1.92% compared to the previous year's $4.13 billion. Earnings were $10.30 million, a decrease of -97.83%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for CRL stock is "Hold." The 12-month stock price forecast is $184.0, which is an increase of 30.16% from the latest price.
News

S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments
The S&P 500 broke a two-session losing streak, rising Wednesday as stocks gained ground in volatile trading following the Federal Reserve's decision to keep interest rates unchanged.

Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2025 Results Conference Call May 7, 2025 9:00 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Ch...

Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization
Charles River Laboratories International Inc CRL stock is trading higher on Wednesday after the company released better than expected first-quarter 2025 earnings.

Charles River Stock Is Having Its Best Day in 13 Years. A Board Shake-Up and Business Review Will Help.
The biotech said its largest investor would conduct a ‘strategic review' as revenue continued to decline.

Top Stock Moves Now: Charles River Labs, Disney, Supermicro, and More
U.S. equities were little changed at midday as the market awaited the Federal Reserve's interest-rate decision coming this afternoon. The Dow Jones Industrial Average was higher, the Nasdaq was lower,...

Charles River to add new directors, review business in agreement with Elliott
Charles River Laboratories said on Wednesday it had reached an agreement with activist investor Elliott Investment Management and added four new directors to its board.

Charles River Laboratories Announces First-Quarter 2025 Results
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces First-Quarter 2025 Financial Results.

Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value.

Exclusive: Charles River agrees with Elliott to add new directors, review business
Pharmaceutical company Charles River Laboratories has reached a settlement with activist investor Elliott Investment Management to add four new directors to its board and launch a strategic review of ...

Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--The Charles River Incubator Program announces its first cohort, expediting the development of technologies and life-changing therapies for patie...

Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Ahead of AACR 2025, Charles River announces updates to its comprehensive portfolio to support the discovery and development of novel oncology dr...

Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules first-quarter 2025 earnings release and conference call.

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform
WILMINGTON, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Valo Health announce the identification of an advanceable product candidate for treatment of lupus and othe...

Charles River Laboratories to Present at Barclays Global Healthcare Conference
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Barclays Global Healthcare Conference.

FairJourney Biologics Acquires Charles River Laboratories South San Francisco Facility
PORTO, Portugal & SAN FRANCISCO--(BUSINESS WIRE)--FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced that it had completed the acquisition of the Sout...

Charles River Announces Agreement with Singapore General Hospital
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River to provide master cell banking and NGS testing services for SGH's cord blood derived allogeneic CAR-T cells.

Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance
On Wednesday, Charles River Laboratories International Inc CRL reported fourth-quarter 2024 revenue of $1 billion, a decrease of 1.1% year over year, beating the consensus of $983.63 million.

Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call February 19, 2025 8:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair,...

Charles River beats quarterly estimates on stable demand for drug development services
Charles River Laboratories on Wednesday beat fourth-quarter profit and revenue estimates, helped by stable demand for its drug discovery and development services from biotech clients.

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance.

Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions
WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Deciphex focus on advancing image management solutions, while developing novel AI tools for toxicologic pathology.

Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call.

Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River expands Apollo ecosystem, offering bespoke client experiences that enable data-driven decision making.

Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Akron Bio (“Akron”), a leading supplier of critical materials and services for advanced therapies, to...